Utah is currently home to 1240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis
NCT05660382
Recruiting
The goal of this clinical trial is to prove the that miconazole oil works well on fungal infections of the ears, by comparing the drug with a placebo. The researcher or the participants will not know if they are getting the drug or the placebo. The researcher will show the participants how to use the drug or placebo. After 14 days of using the drug or placebo, the participants will be examined by the researcher and graded on how well the drug worked on the ear(s) fungal infection. Participants w... Read More
Gender:
All
Ages:
All
Trial Updated:
01/15/2024
Locations: ENT Center Of Utah, Salt Lake City, Utah
Conditions: Otomycosis
Register for Updates
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
NCT05987189
Recruiting
2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/12/2024
Locations: University Of Utah Health, Salt Lake City, Utah
Conditions: Lung Cancer
Register for Updates
TRISCEND II Pivotal Trial
NCT04482062
Recruiting
Pivotal trial to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
Register for Updates
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949
Recruiting
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Register for Updates
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
NCT02089217
Recruiting
Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. Medical ma... Read More
Gender:
All
Ages:
Between 35 years and 100 years
Trial Updated:
01/12/2024
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Carotid Stenosis
Register for Updates
First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
NCT05781399
Recruiting
The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailability between a tablet and suspension formulation of JNT-517 and the food effect in healthy volunteers. All participants in Part C will receive JNT-517. The goal of Part D is to assess the safety, tolera... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/11/2024
Locations: Utah Health - The University of Utah Hospital, Salt Lake City, Utah
Conditions: Phenylketonuria
Register for Updates
Phase 2b Study of ALTO-100 in MDD
NCT05712187
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
01/10/2024
Locations: Site 121, Draper, Utah
Conditions: Major Depressive Disorder
Register for Updates
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NCT05438212
Recruiting
This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Metastatic Malignant Neoplasm in the Brain
Register for Updates
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051
Recruiting
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: GSK Investigational Site, Salt Lake City, Utah
Conditions: Neoplasms
Register for Updates
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376
Recruiting
This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and s... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
01/09/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
C-Brace Prospective Registry
NCT04640584
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
All
Ages:
All
Trial Updated:
01/09/2024
Locations: Freedom P & O - 356 E 600 S, Saint George, Utah
Conditions: Pareses, Lower Extremity
Register for Updates
Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.
NCT05831995
Recruiting
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated advanced solid tumors as ABM-168 may have a significant effect in inhibiting cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/08/2024
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
Register for Updates